Additional codes related to COVID-19

The National Board of Health and Welfare announces that from February 1, two new codes will be introduced, one of which may be relevant in intensive care.

It is U11.9 Contact for vaccination against COVID-19 (probably not current in ICU) and U12.9 - Vaccine against COVID-19 in therapeutic use as the cause of adverse efficacy.

Examples of use:
After vaccination, a patient exhibits an anaphylactic shock and is transferred to ICU for treatment and/or observation.
For the time of care, the following information is:
T88.6 Anaphylactic shock caused by adequate medicinal product or medical substance prescribed and administered correctly (possibly as main ICU diagnosis)
U12.9 - Vaccine against COVID-19 in therapeutic use as a cause of adverse efficacy (as otherwise diagnosed)